German group Merck to buy Bio-Techne in $11.3bn deal
Summary
Merck agreed to buy US medical tools maker Bio-Techne for $11.3bn, marking its biggest acquisition in more than a decade. The deal expands Merck’s life sciences tools footprint in a market driven by bioprocessing and lab demand.
Why it matters
It signals renewed big-ticket consolidation in life sciences tools and could reset competitive dynamics and pricing across labs and biomanufacturing.